logo
  

Valneva, Pfizer Report Positive Phase 2 Pediatric Data For Lyme Disease Vaccine Candidate, VLA15

Valneva SE (VLA), a specialty vaccine company, and Pfizer Inc. (PFE) reported Tuesday positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Based on these new results, the companies plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial.

The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval.

The Phase 2 trial, VLA15-221, is the first clinical study with VLA15 which enrolled a pediatric population between 5 and 17 years old. It compared the immunogenicity and safety of VLA15 after administration of two or three primary series doses in groups aged 5-11, 12-17 and 18-65 years.

In pediatric participants who received VLA15 in either the two-dose schedule or three-dose schedule, VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested.

Like in adults, the immunogenicity and safety data support a three-dose primary vaccination schedule in pediatric participants in the Phase 3 study.

The companies noted that the safety and tolerability profile observed in the 5- to 17-year age group was similar to the previously reported profile in adult participants. No vaccine-related serious adverse events or SAEs were observed.

Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula. Shares of Deutsche Telekom AG were gaining more than 1 percent in the morning trading in Germany after the telecom major on Thursday raised its fiscal 2022 earnings outlook again, despite reporting lower profit in its second quarter. Adjusted EBITDA AL, a key earnings metric, increased, while adjusted EBITDA AL margin dropped.
Follow RTT